Patents by Inventor Roni Wechsler

Roni Wechsler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening systems utilizing RTP801
    Patent number: 8344104
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: January 1, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roni Wechsler, Igor Mett, Elena Feinstein
  • SCREENING SYSTEMS UTILIZING RTP801
    Publication number: 20120034599
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Application
    Filed: August 26, 2011
    Publication date: February 9, 2012
    Inventors: Roni Wechsler, Igor Mett
  • Screening systems utilizing RTP801
    Patent number: 8034575
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors to and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: October 11, 2011
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roni Wechsler, Igor Mett, Elena Feinstein
  • Screening systems utilizing RTP801
    Publication number: 20110045499
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors to and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Application
    Filed: May 21, 2010
    Publication date: February 24, 2011
    Inventors: Roni Wechsler, Igor Mett, Elena Feinstein
  • Screening systems utilizing RTP801
    Patent number: 7723052
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 25, 2010
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roni Wechsler, Igor Mett
  • Screening systems utilizing RTP801L
    Publication number: 20080014599
    Abstract: RTP801L represents a unique gene target for hypoxia-inducible factor-1 (HIF-1) that may regulate hypoxia-induced pathogenesis; down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801L. The present invention relates to screening systems utilizing RTP801L and/or RTP801L interactors and/or RTP801L biological activity, and to the potential drugs and methods of treatment identified by such screening systems.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 17, 2008
    Inventors: Roni Wechsler, Igor Mett
  • Screening systems utilizing RTP801
    Publication number: 20070281326
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Application
    Filed: May 11, 2007
    Publication date: December 6, 2007
    Inventors: Roni Wechsler, Igor Mett